Clinical trials: Lung Tumors
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Pulmonary sarcomatoid_MEDI4736+Treme
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
- Trial name
- NCT03022500
- Testing
- durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer…
- Trial name
- NCT07063407
- Testing
- HS-20093 in combination with Adebrelimab
- Volunteers
- 50 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Lung Cancer, Brain Tumor
The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
1. Eligible participants were assessed prior to anesthesia. After the patient is admitted to the hospital, the subject's consent form is explained, and the consent form must be signed before the operation. 2.
- Conditions
- Lung Cancer, Brain Tumor, Liver Cancer, Ovarian Cancer
- Trial name
- NCT05926336
- Testing
- Propofol, Sevoflurane
- Where
- Taiwan
- Volunteers
- 1,316 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.
Small Cell Lung Carcinoma
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
This single-arm, Phase II study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) combination with Apatinib in participants with ES-SCLC who was response or stable…
- Trial name
- CAMERA (NCT04901754)
- Testing
- Camrelizumab Plus Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer
Perfusion CT Imaging in Lung Cancer With SBRT
The goal of this study is to determine specific perfusion patterns for radiation induced lung changes and residual/recurrent lung malignancies in patients treated with stereotactic body radiotherapy SBRT and thus improve to…
- Trial name
- NCT02755454
- Testing
- Perfusion CT Imaging
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Lung Cancer
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.
- Trial name
- NCT00022022
- Testing
- docetaxel, quality-of-life assessment
- Where
- 16 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Nazionale per lo Studio e la Cura dei Tumori
Tumor, COVID-19
Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19.
- Trial name
- NCT06006845
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Seventh Affiliated Hospital of Sun Yat-sen University
Lung Neoplasm
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC.
- Trial name
- VINCR (NCT00295672)
- Testing
- Vinorelbine
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Brest
Lung Cancer
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
The combination of neoadjuvant immunotherapy plus chemotherapy has recently been shown to improve survival outcome compared to chemotherapy alone and was recently approved for resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT06055465
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 4 sites in Hong Kong
- Volunteers
- 37 people
- Sponsor
- Chinese University of Hong Kong
Lung Neoplasms, Bronchoscopy
Feasibility and Preliminary Performance of an AI Prototype for Digital ROSE During EBUS-TBNA and Peripheral TBNA: a Prospective Pilot Study (AI-ROSE-FEAS)
Rapid On-Site Evaluation (ROSE) of cytological slides obtained during EBUS-TBNA improves diagnostic yield by providing real-time adequacy assessment and preliminary diagnostic orientation after each needle pass.
- Conditions
- Lung Neoplasms, Bronchoscopy, AI (Artificial Intelligence), Mediastinal ( Chest) Masses
- Trial name
- AI-ROSE-FEAS (NCT07662967)
- Testing
- ROSE
- Volunteers
- 65 people
- Sponsor
- Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli
Lung Cancer
Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with stage III…
- Trial name
- NCT00003154
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Squamous Non-small Cell Lung Cancer
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
This study is a prospective, single arm, single center open clinical study aimed at evaluating the efficacy and safety of recombinant human endostatin and envafolimab combined with synchronal radiochemotherapy in patients with…
- Trial name
- NCT06279754
- Testing
- Recombinant Human Endostatin Injection
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
NSCLC Stage IIIB~IV
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
- Trial name
- NCT04147351
- Testing
- Atezolizumab Injection; bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor under domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit…
- Trial name
- NCT04619537
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Cancer, Pulmonary Nodule, Solitary
Application of Carbon Dioxide for Identifying the Intersegmental Plane in Thoracoscopic Segmentectomy
With the increasing acceptance of routine computed tomography (CT) screenings, early-stage lung cancer detection is becoming more frequent.
- Conditions
- Lung Cancer, Pulmonary Nodule, Solitary, Segmentectomy, Pulmonary Nodule, Multiple
- Trial name
- NCT05350137
- Testing
- 100% oxygen, Carbon dioxide
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tongji Hospital
Small Cell Lung Cancer, Brain Metastasis
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.
- Trial name
- NCT02425072
- Testing
- NovoTTF-100A plus chemotherapy
- Where
- United States
- Sponsor
- John Villano
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Non Small Cell Lung Cancer, CNS Progression
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
This trial is testing two novel combinations (temozolomide plus osimertinib OR temozolomide plus lorlatinib) which have not been evaluated in clinical trials. Thus, the exact benefits of these novel combinations are unclear.
- Trial name
- NCT04541407
- Testing
- Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.